-
Shoreline Biosciences Announces $140M Financing To Advance Its Growing Pipeline Of Next Generation Cell Immunotherapies
-
Financing accelerates the growth of Shoreline’s pipeline of iPSC-based cell immunotherapies for the treatment of seriously ill patients and enables the buildout of smart manufacturing capabilities.
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
Cord for Life®, Inc. Announces Cord Blood Clinical Trial Phase I Trial for the Treatment of Lower Back Pain of the Sacroiliac Joint
Altamonte Springs, FL, October 29, 2021 — Cord for Life®, a full-service cord blood bank with over 25 years of experience, today announced plans to conduct a clinical trial to treat lower back pain arising from the Sacroiliac Joint (SIJ) using a biological therapeutic derived from umbilical cord blood. [Read more…]
Vitti Labs Announces FDA Approval of IND Application for Phase II Trial of Combination MSC and Exosome Treatment of COVID-19
LIBERTY, Mo., Oct. 26, 2021 — Vitti Labs (www.vittilabs.com), an AATB Accredited Tissue Bank focused on Life Science Research, Development and Manufacturing, announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to conduct Phase II Clinical Trials using a combination of Umbilical Cord Mesenchymal Stem Cell and Umbilical Cord Mesenchymal Stem Cell Exosomes for the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with the Novel Corona Virus (COVID-19). This marks the very first time the FDA has approved an IND that uses both of these components together and so first of its kind therapy. [Read more…]
Curi Bio and NEXEL Form Celogics, a Joint Venture to Develop iPSC-Derived Products
Celogics, based in Seattle, will offer high-quality iPSC-derived cell products for drug discovery and safety testing.
OCTOBER 26, 2021, SEATTLE and SEOUL – Curi Bio, a global leader in development of human stem cell-based platforms for disease modeling and drug discovery, and NEXEL, a leader in induced pluripotent stem cell (iPSC) technology, today announced the formation of Celogics, a joint venture company focused on the development and commercialization of human iPSC-derived cell products for drug discovery, drug safety testing, and biological research. Celogics iPSC production and distribution headquarters will be located in Seattle, WA. [Read more…]
Bone Therapeutics Signs Research Partnership with Implant Therapeutics to Access iPSCs
-
Bone Therapeutics has partnered with Implant Therapeutics to gain access to iPSC derived, genetically engineered MSCs. These
-
Bone Therapeutics will gain access to iPS cell lines, including hypoimmunogenic cell lines, differentiation protocols and expertise
- « Previous Page
- 1
- …
- 43
- 44
- 45
- 46
- 47
- …
- 123
- Next Page »